T2 Biologics for Chronic Obstructive Pulmonary Disease

医学 重症监护医学 肺病 内科学 梅德林 慢性病 政治学 法学
作者
Ahmed Yousuf,Wadah Ibrahim,Neil Greening,Christopher E. Brightling
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:7 (5): 1405-1416 被引量:47
标识
DOI:10.1016/j.jaip.2019.01.036
摘要

Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third leading cause of death and disability worldwide by 2030. Recent advances in understanding the underlying pathophysiology of COPD has led to the development of novel targeted therapies (biologics and small molecules) that address the underlying pathophysiology of the disease. In severe asthma, biologics targeting type 2 (T2)- mediated immunity have been successful and have changed the treatment paradigm. In contrast, no biologics are currently licensed for the treatment of COPD. Those targeting non-T2 pathways have not demonstrated efficacy and in some cases raised concerns related to safety. With the increasing recognition of the eosinophil and perhaps T2-immunity possibly playing a role in a subgroup of patients with COPD, T2 biologics, specifically anti–IL-5(R), have been tested and demonstrated modest reductions in exacerbation frequency. Potential benefit was related to the baseline blood eosinophil count. These benefits were small compared with asthma. Thus, whether a subgroup of COPD sufferers might respond to anti–IL-5 or other T2-directed biologics remains to be fully addressed and requires further investigation. Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third leading cause of death and disability worldwide by 2030. Recent advances in understanding the underlying pathophysiology of COPD has led to the development of novel targeted therapies (biologics and small molecules) that address the underlying pathophysiology of the disease. In severe asthma, biologics targeting type 2 (T2)- mediated immunity have been successful and have changed the treatment paradigm. In contrast, no biologics are currently licensed for the treatment of COPD. Those targeting non-T2 pathways have not demonstrated efficacy and in some cases raised concerns related to safety. With the increasing recognition of the eosinophil and perhaps T2-immunity possibly playing a role in a subgroup of patients with COPD, T2 biologics, specifically anti–IL-5(R), have been tested and demonstrated modest reductions in exacerbation frequency. Potential benefit was related to the baseline blood eosinophil count. These benefits were small compared with asthma. Thus, whether a subgroup of COPD sufferers might respond to anti–IL-5 or other T2-directed biologics remains to be fully addressed and requires further investigation. Biologics, Clinical Context, and the AsthmasThe Journal of Allergy and Clinical Immunology: In PracticeVol. 7Issue 5PreviewIt has been more than 15 years since the US Food and Drug Administration approved omalizumab for the therapy of moderate-to-severe perennial allergic asthma. The concept of removing one of the key triggers of asthma, IgE, excited the scientific and medical community. Indeed, with 80% of children and 50% of adults having a significant allergic trigger to their asthma, it was envisioned that this approach could lead to long-standing remission or perhaps even a cure for many patients. Moreover, serum IgE levels had been shown to be increased in smokers, implicating a potential role for IgE in the pathogenesis of smoking-related lung diseases such as chronic obstructive pulmonary disease (COPD). Full-Text PDF CME Exam: T2 Biologics for Chronic Obstructive Pulmonary DiseaseThe Journal of Allergy and Clinical Immunology: In PracticeVol. 7Issue 5Preview Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
积极的以亦完成签到,获得积分10
1秒前
CodeCraft应助VV采纳,获得10
1秒前
大牛顿发布了新的文献求助10
2秒前
善学以致用应助siyin采纳,获得10
3秒前
弥生妖刀完成签到,获得积分10
3秒前
3秒前
4秒前
tyy发布了新的文献求助10
4秒前
酷炫翠桃应助多情万宝路采纳,获得10
4秒前
小金鱼儿发布了新的文献求助10
4秒前
天天快乐应助Albertxkcj采纳,获得10
4秒前
negolos完成签到,获得积分10
4秒前
Tac1完成签到,获得积分10
4秒前
5秒前
5秒前
schnappi完成签到,获得积分10
5秒前
Stefani发布了新的文献求助30
6秒前
三七发布了新的文献求助10
7秒前
小白发布了新的文献求助10
8秒前
zzj512682701完成签到,获得积分10
8秒前
pepsisery完成签到,获得积分10
8秒前
8秒前
晓军发布了新的文献求助10
9秒前
9秒前
小六发布了新的文献求助10
10秒前
赘婿应助靓丽的海亦采纳,获得10
10秒前
11秒前
roser发布了新的文献求助10
12秒前
z1z1z发布了新的文献求助20
13秒前
13秒前
HAL9000完成签到,获得积分10
13秒前
14秒前
zzj512682701发布了新的文献求助10
14秒前
14秒前
典雅碧空应助小涛采纳,获得10
14秒前
苏夏完成签到 ,获得积分10
14秒前
biomichael发布了新的文献求助10
14秒前
情怀应助ottsannn采纳,获得10
15秒前
顾矜应助楼松思采纳,获得10
15秒前
量子星尘发布了新的文献求助10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969458
求助须知:如何正确求助?哪些是违规求助? 3514286
关于积分的说明 11173363
捐赠科研通 3249652
什么是DOI,文献DOI怎么找? 1794948
邀请新用户注册赠送积分活动 875501
科研通“疑难数据库(出版商)”最低求助积分说明 804836